1)Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System. IARC Press, Lyon, 2010
2)日本神経内分泌腫瘍研究会(編).膵・消化管神経内分泌腫瘍(NET)診療ガイドライン,第1版.金原出版,2015
3)Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma:a clinicopathologic study. Gastroenterology 104:994-1006, 1993
4)Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45:234-243, 2010
5)Soga J. Early-stage carcinoids of the gastrointestinal tract:an analysis of 1,914 reported cases. Cancer 103:1587-1595, 2005
6)Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors:well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas 39:753-766, 2010
7)Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 15:966-973, 2004
8)Clark OH, Benson AB 3rd, Berlin JD, et al. NCCN Clinical Practice Guidelines in Oncology:neuroendocrine tumors. J Natl Compr Canc Netw 7:712-747, 2009
9)Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract(RADIANT-4):a randomized, placebo-controlled, phase 3 study. Lancet 387:968-977, 2016